[
  {
    "title": "奥泰生物(688606.SH)：“新增年产2.65亿人份体外诊断试剂的产业化升级技术改造项目”已实现投产",
    "href": "http://stock.jrj.com.cn/2023/01/02170537253197.shtml",
    "datetime": "2023-01-02 17:05:45",
    "code": "688606"
  },
  {
    "title": "奥泰生物(688606.SH)：董事、高管、核心技术人员陆维克拟减持不超10万股",
    "href": "http://stock.jrj.com.cn/2022/12/12162837205935.shtml",
    "datetime": "2022-12-12 16:28:19",
    "code": "688606"
  },
  {
    "title": "奥泰生物(688606.SH)：完成回购 累计耗资约1.15亿元回购1.92%股份",
    "href": "http://stock.jrj.com.cn/2022/09/30210437035345.shtml",
    "datetime": "2022-09-30 21:04:52",
    "code": "688606"
  },
  {
    "title": "奥泰生物(688606.SH)：股东徐建明减持期过半未减持",
    "href": "http://stock.jrj.com.cn/2022/09/30163737034172.shtml",
    "datetime": "2022-09-30 16:37:11",
    "code": "688606"
  },
  {
    "title": "奥泰生物(688606.SH)：245万股限售股份将于9月26日上市流通",
    "href": "http://stock.jrj.com.cn/2022/09/15171336997577.shtml",
    "datetime": "2022-09-15 17:13:04",
    "code": "688606"
  },
  {
    "title": "奥泰生物(688606.SH)：截至9月14日已累计回购1.0154%股份",
    "href": "http://stock.jrj.com.cn/2022/09/14160036994149.shtml",
    "datetime": "2022-09-14 16:00:45",
    "code": "688606"
  },
  {
    "title": "奥泰生物(688606.SH)截至8月底已累计回购7.7341万股",
    "href": "http://stock.jrj.com.cn/2022/08/31161636958216.shtml",
    "datetime": "2022-08-31 16:16:55",
    "code": "688606"
  },
  {
    "title": "奥泰生物：2022年半年实现净利润13.03亿元，同比增长299.48%",
    "href": "http://stock.jrj.com.cn/2022/08/25174236936352.shtml",
    "datetime": "2022-08-25 17:42:08",
    "code": "688606"
  },
  {
    "title": "奥泰生物(688606.SH)：近期获得欧盟质量管理体系证书、A族链球菌检测试剂等产品获得IVDR CE认证",
    "href": "http://stock.jrj.com.cn/2022/07/25172536840411.shtml",
    "datetime": "2022-07-25 17:25:19",
    "code": "688606"
  },
  {
    "title": "A股异动 | 奥泰生物(688606.SH)盘中涨超8% 将花不超1.16亿元回购",
    "href": "http://stock.jrj.com.cn/2022/07/25102336839165.shtml",
    "datetime": "2022-07-25 10:23:08",
    "code": "688606"
  },
  {
    "title": "奥泰生物将花不超1.16亿元回购公司股份 用于股权激励计划",
    "href": "http://stock.jrj.com.cn/2022/07/22205136836990.shtml",
    "datetime": "2022-07-22 20:51:59",
    "code": "688606"
  },
  {
    "title": "奥泰生物(688606.SH)：向激励对象授予72万股限制性股票",
    "href": "http://stock.jrj.com.cn/2022/07/22204236836982.shtml",
    "datetime": "2022-07-22 20:42:04",
    "code": "688606"
  },
  {
    "title": "奥泰生物(688606.SH)：拟斥0.9亿元-1.155亿元回购公司股份",
    "href": "http://stock.jrj.com.cn/2022/07/22173736836256.shtml",
    "datetime": "2022-07-22 17:37:52",
    "code": "688606"
  },
  {
    "title": "奥泰生物(688606.SH)：拟使用不超18亿元暂时闲置自有资金进行现金管理",
    "href": "http://stock.jrj.com.cn/2022/06/27182836761997.shtml",
    "datetime": "2022-06-27 18:28:08",
    "code": "688606"
  },
  {
    "title": "奥泰生物(688606.SH)：拟使用不超2亿元暂时闲置募集资金进行现金管理",
    "href": "http://stock.jrj.com.cn/2022/06/27182736762000.shtml",
    "datetime": "2022-06-27 18:27:08",
    "code": "688606"
  },
  {
    "title": "奥泰生物(688606.SH)：赢海生物以1800万元竞拍取得相关项目用地",
    "href": "http://stock.jrj.com.cn/2022/06/22160436749710.shtml",
    "datetime": "2022-06-22 16:04:59",
    "code": "688606"
  },
  {
    "title": "奥泰生物(688606)：5%以上股东减持股份计划",
    "href": "http://stock.jrj.com.cn/2022/06/10085836718030.shtml",
    "datetime": "2022-06-10 08:58:34",
    "code": "688606"
  },
  {
    "title": "奥泰生物：股东徐建明因自身资金需要 拟减持不超1.86%公司股份",
    "href": "http://stock.jrj.com.cn/2022/06/09172536716435.shtml",
    "datetime": "2022-06-09 17:25:13",
    "code": "688606"
  },
  {
    "title": "奥泰生物(688606.SH)：股东徐建明拟减持不超1.86%股份",
    "href": "http://stock.jrj.com.cn/2022/06/09160936715873.shtml",
    "datetime": "2022-06-09 16:09:03",
    "code": "688606"
  },
  {
    "title": "奥泰生物(688606.SH)2021年度权益分派10派40元 股权登记日为6月6日",
    "href": "http://stock.jrj.com.cn/2022/05/30171436690041.shtml",
    "datetime": "2022-05-30 17:14:12",
    "code": "688606"
  },
  {
    "title": "奥泰生物(688606.SH)：4项检测产品获得欧盟CE List A认证",
    "href": "http://stock.jrj.com.cn/2022/05/23170036670691.shtml",
    "datetime": "2022-05-23 17:00:02",
    "code": "688606"
  },
  {
    "title": "奥泰生物拟使用6.4亿元超募资金投资年产4亿人份体外诊断试剂生产研发中心建设项目",
    "href": "http://stock.jrj.com.cn/2022/05/09102136603195.shtml",
    "datetime": "2022-05-09 10:21:52",
    "code": "688606"
  },
  {
    "title": "奥泰生物(688606.SH)：计划新建年产4亿人份体外诊断试剂生产研发中心建设项目",
    "href": "http://stock.jrj.com.cn/2022/05/08204936598221.shtml",
    "datetime": "2022-05-08 20:49:49",
    "code": "688606"
  },
  {
    "title": "奥泰生物2022年第一季度净利10.49亿同比增长598.18% 新冠抗原检测产品收入增长",
    "href": "http://stock.jrj.com.cn/2022/05/03191136546524.shtml",
    "datetime": "2022-05-03 19:11:44",
    "code": "688606"
  },
  {
    "title": "奥泰生物2021年净利7.66亿同比增长12.73% 董事长高飞薪酬82.94万",
    "href": "http://stock.jrj.com.cn/2022/05/02173236533034.shtml",
    "datetime": "2022-05-02 17:32:46",
    "code": "688606"
  },
  {
    "title": "奥泰生物(688606.SH)：2021年度净利润增12.73%至7.66亿元 拟10派40元",
    "href": "http://stock.jrj.com.cn/2022/04/28144336492465.shtml",
    "datetime": "2022-04-28 14:43:29",
    "code": "688606"
  },
  {
    "title": "奥泰生物(688606.SH)：一季度净利润增598.18%至10.49亿元",
    "href": "http://stock.jrj.com.cn/2022/04/28144036492467.shtml",
    "datetime": "2022-04-28 14:40:36",
    "code": "688606"
  },
  {
    "title": "奥泰生物披露2021年年报 实现营收18.73亿元",
    "href": "http://stock.jrj.com.cn/2022/04/28092436490658.shtml",
    "datetime": "2022-04-28 09:24:01",
    "code": "688606"
  },
  {
    "title": "奥泰生物(688606.SH)拟不少于4亿元投建新诊断试剂研发及生产项目",
    "href": "http://stock.jrj.com.cn/2022/04/27224736487156.shtml",
    "datetime": "2022-04-27 22:47:43",
    "code": "688606"
  },
  {
    "title": "振德医疗(603301.SH)：子公司与奥泰生物签订关于新冠抗原检测试剂盒战略合作框架协议书",
    "href": "http://stock.jrj.com.cn/2022/04/12172936315886.shtml",
    "datetime": "2022-04-12 17:29:01",
    "code": "688606"
  },
  {
    "title": "奥泰生物(688606.SH)：与振德健康签订关于新冠抗原检测试剂盒战略合作框架协议书",
    "href": "http://stock.jrj.com.cn/2022/04/12165836315726.shtml",
    "datetime": "2022-04-12 16:58:19",
    "code": "688606"
  },
  {
    "title": "奥泰生物：与振德医疗子公司签订新冠抗原检测试剂盒战略合作框架协议书",
    "href": "http://stock.jrj.com.cn/2022/04/12165736315722.shtml",
    "datetime": "2022-04-12 16:57:30",
    "code": "688606"
  },
  {
    "title": "奥泰生物一字板涨停 一季度净利预增585.40%-691.87%",
    "href": "http://stock.jrj.com.cn/2022/03/29093736074223.shtml",
    "datetime": "2022-03-29 09:37:42",
    "code": "688606"
  },
  {
    "title": "A股异动 | 奥泰生物(688606.SH)涨停 一季度净利润同比预增585.4%至691.87%",
    "href": "http://stock.jrj.com.cn/2022/03/29093336074237.shtml",
    "datetime": "2022-03-29 09:33:36",
    "code": "688606"
  },
  {
    "title": "奥泰生物22年一季度预计净利10.3亿-11.9亿同比增加585%-692% 新冠检测业务订单增长",
    "href": "http://stock.jrj.com.cn/2022/03/28215235947093.shtml",
    "datetime": "2022-03-28 21:52:25",
    "code": "688606"
  },
  {
    "title": "奥泰生物：预计一季度净利同比增长585%-692%",
    "href": "http://stock.jrj.com.cn/2022/03/28172235894391.shtml",
    "datetime": "2022-03-28 17:22:06",
    "code": "688606"
  },
  {
    "title": "奥泰生物(688606.SH)：一季度净利预增585.40%-691.87%",
    "href": "http://stock.jrj.com.cn/2022/03/28171735893941.shtml",
    "datetime": "2022-03-28 17:17:13",
    "code": "688606"
  },
  {
    "title": "奥泰生物(688606.SH)：新冠病毒抗原检测试剂盒(乳胶法)国内获批上市",
    "href": "http://stock.jrj.com.cn/2022/03/21155634855742.shtml",
    "datetime": "2022-03-21 15:56:39",
    "code": "688606"
  },
  {
    "title": "奥泰生物：新型冠状病毒抗原检测试剂盒取得国内医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/03/21155334855728.shtml",
    "datetime": "2022-03-21 15:53:47",
    "code": "688606"
  },
  {
    "title": "奥泰生物(688606.SH)：969.5万股限售股将解禁",
    "href": "http://stock.jrj.com.cn/2022/03/15174134829873.shtml",
    "datetime": "2022-03-15 17:41:31",
    "code": "688606"
  },
  {
    "title": "奥泰生物2021年净利7.61亿同比增长12.11% 新冠检测试剂销量持续增长",
    "href": "http://stock.jrj.com.cn/2022/02/25185134465603.shtml",
    "datetime": "2022-02-25 18:51:51",
    "code": "688606"
  },
  {
    "title": "华海药业(600521.SH)：拟对华奥泰生物实施第二期员工股权激励",
    "href": "http://stock.jrj.com.cn/2022/01/20160534178609.shtml",
    "datetime": "2022-01-20 16:05:16",
    "code": "688606"
  },
  {
    "title": "奥泰生物2021年预计净利7.05亿-7.95亿同比增加4%-17% 新冠检测业务保持稳定增长",
    "href": "http://stock.jrj.com.cn/2022/01/14204834159153.shtml",
    "datetime": "2022-01-14 20:48:37",
    "code": "688606"
  },
  {
    "title": "奥泰生物(688606.SH)：2021年度净利预增3.78%-17.05%",
    "href": "http://stock.jrj.com.cn/2022/01/14174634158313.shtml",
    "datetime": "2022-01-14 17:46:26",
    "code": "688606"
  },
  {
    "title": "奥泰生物拟投资3000万美元在浙江海宁设立全资子公司",
    "href": "http://stock.jrj.com.cn/2022/01/07204734135000.shtml",
    "datetime": "2022-01-07 20:47:26",
    "code": "688606"
  },
  {
    "title": "奥泰生物(688606.SH)：子公司拟以3000万美元投设浙江赢海生物技术",
    "href": "http://stock.jrj.com.cn/2022/01/07155834133584.shtml",
    "datetime": "2022-01-07 15:58:07",
    "code": "688606"
  },
  {
    "title": "奥泰生物(688606.SH)：子公司拟与关联方共同对瑞测生物、逸乐生物进行投资",
    "href": "http://stock.jrj.com.cn/2021/12/03171133960579.shtml",
    "datetime": "2021-12-03 17:11:33",
    "code": "688606"
  },
  {
    "title": "奥泰生物拟对外投资2000万在钱塘区设立全资子公司",
    "href": "http://stock.jrj.com.cn/2021/11/22190033904993.shtml",
    "datetime": "2021-11-22 19:00:17",
    "code": "688606"
  },
  {
    "title": "奥泰生物(688606.SH)：拟使用2000万元设杭州奥恺生物",
    "href": "http://stock.jrj.com.cn/2021/11/22154033903821.shtml",
    "datetime": "2021-11-22 15:40:34",
    "code": "688606"
  },
  {
    "title": "奥泰生物：前三季度净利润4.82亿元，同比增长27.71%",
    "href": "http://stock.jrj.com.cn/2021/10/31212633785396.shtml",
    "datetime": "2021-10-31 21:26:28",
    "code": "688606"
  },
  {
    "title": "奥泰生物(688606.SH)：第三季度净利润升148.8%至1.56亿元",
    "href": "http://stock.jrj.com.cn/2021/10/29201533779591.shtml",
    "datetime": "2021-10-29 20:15:18",
    "code": "688606"
  },
  {
    "title": "奥泰生物(688606.SH)：控股股东、实控人及部分董事、高管延长股份锁定期6个月",
    "href": "http://stock.jrj.com.cn/2021/09/24161033510224.shtml",
    "datetime": "2021-09-24 16:10:17",
    "code": "688606"
  },
  {
    "title": "奥泰生物(688606.SH)：55.41万股限售股将于9月27日起上市流通",
    "href": "http://stock.jrj.com.cn/2021/09/13155433428460.shtml",
    "datetime": "2021-09-13 15:54:16",
    "code": "688606"
  },
  {
    "title": "奥泰生物2021年半年度净利3.26亿元 同比净利增加3.57%",
    "href": "http://stock.jrj.com.cn/2021/08/19210133282565.shtml",
    "datetime": "2021-08-19 21:01:33",
    "code": "688606"
  },
  {
    "title": "奥泰生物(688606.SH)：上半年净利增3.57%至3.26亿元",
    "href": "http://stock.jrj.com.cn/2021/08/19162533280649.shtml",
    "datetime": "2021-08-19 16:25:29",
    "code": "688606"
  },
  {
    "title": "奥泰生物拟使用自有资金合计2000万设立全资子公司",
    "href": "http://stock.jrj.com.cn/2021/07/29213733171601.shtml",
    "datetime": "2021-07-29 21:37:47",
    "code": "688606"
  },
  {
    "title": "奥泰生物(688606.SH)：拟使用2000万元在钱塘新区设全资子公司",
    "href": "http://stock.jrj.com.cn/2021/07/29154133169577.shtml",
    "datetime": "2021-07-29 15:41:07",
    "code": "688606"
  },
  {
    "title": "奥泰生物：使用募集资金置换预先投入自筹资金",
    "href": "http://stock.jrj.com.cn/2021/06/12060532914921.shtml",
    "datetime": "2021-06-12 06:05:57",
    "code": "688606"
  },
  {
    "title": "奥泰生物(688606.SH)：拟使用最高余额不超2亿元暂时闲置募集资金进行现金管理",
    "href": "http://stock.jrj.com.cn/2021/06/11160032911429.shtml",
    "datetime": "2021-06-11 16:00:37",
    "code": "688606"
  },
  {
    "title": "奥泰生物(688606.SH)：拟将超募资金投资在建的年产2亿人份体外诊断试剂生产中心及研发中心建设项目",
    "href": "http://stock.jrj.com.cn/2021/06/11155832911406.shtml",
    "datetime": "2021-06-11 15:58:44",
    "code": "688606"
  },
  {
    "title": "奥泰生物：2020年年度权益分派实施 每10股派发现金红利20元（含税）",
    "href": "http://stock.jrj.com.cn/2021/06/03163532869642.shtml",
    "datetime": "2021-06-03 16:35:03",
    "code": "688606"
  },
  {
    "title": "奥泰生物(688606.SH)：2020年度拟10派20元 6月9日股权登记",
    "href": "http://stock.jrj.com.cn/2021/06/03161332869411.shtml",
    "datetime": "2021-06-03 16:13:26",
    "code": "688606"
  },
  {
    "title": "奥泰生物：公司新冠检测产品涵盖了分子检测、抗体检测和抗原检测三大类",
    "href": "http://stock.jrj.com.cn/2021/04/30095232485032.shtml",
    "datetime": "2021-04-30 09:52:33",
    "code": "688606"
  },
  {
    "title": "奥泰生物2020年净利增长766.15% 董事长高飞薪酬84.11万",
    "href": "http://stock.jrj.com.cn/2021/04/29140432479600.shtml",
    "datetime": "2021-04-29 14:04:53",
    "code": "688606"
  },
  {
    "title": "大手笔！奥泰生物拟每10股派20元 合计派现1.08亿元",
    "href": "http://stock.jrj.com.cn/2021/04/28131432470939.shtml",
    "datetime": "2021-04-28 13:14:05",
    "code": "688606"
  },
  {
    "title": "奥泰生物(688606.SH)一季度净利润1.5亿元 同比增长368.54%",
    "href": "http://stock.jrj.com.cn/2021/04/27225732466074.shtml",
    "datetime": "2021-04-27 22:57:34",
    "code": "688606"
  },
  {
    "title": "A股体外诊断板块添新兵 奥泰生物成功登陆科创板",
    "href": "http://stock.jrj.com.cn/2021/03/26101432221898.shtml",
    "datetime": "2021-03-26 10:14:00",
    "code": "688606"
  },
  {
    "title": "奥泰生物(688606.SH)：公司股票3月25日起上市交易",
    "href": "http://stock.jrj.com.cn/2021/03/23192832203265.shtml",
    "datetime": "2021-03-23 19:28:27",
    "code": "688606"
  },
  {
    "title": "奥泰生物(688606.SH)披露上市发行结果：遭弃购8445股 由承销商包销",
    "href": "http://stock.jrj.com.cn/2021/03/18191732158757.shtml",
    "datetime": "2021-03-18 19:17:32",
    "code": "688606"
  },
  {
    "title": "【兑奖啦】科创板星球石墨、奥泰生物网上申购中签号出炉",
    "href": "http://stock.jrj.com.cn/ipo/2021/03/16193432146720.shtml",
    "datetime": "2021-03-16 19:34:47",
    "code": "688606"
  },
  {
    "title": "奥泰生物(688606.SH)：申银万国创新证投获配44.8866万股 网上摇号中签号共10306个",
    "href": "http://stock.jrj.com.cn/2021/03/16191132146642.shtml",
    "datetime": "2021-03-16 19:11:50",
    "code": "688606"
  },
  {
    "title": "奥泰生物(688606.SH)：网上发行最终中签率为0.02925565%",
    "href": "http://stock.jrj.com.cn/2021/03/15190732138086.shtml",
    "datetime": "2021-03-15 19:07:52",
    "code": "688606"
  },
  {
    "title": "科创板奥泰生物今日申购：2020年净利增超7倍，监管收紧或引起业绩波动",
    "href": "http://stock.jrj.com.cn/ipo/2021/03/15091032134015.shtml",
    "datetime": "2021-03-15 09:10:45",
    "code": "688606"
  },
  {
    "title": "今日新股申购：奥泰生物、星球石墨",
    "href": "http://stock.jrj.com.cn/2021/03/15085032134056.shtml",
    "datetime": "2021-03-15 08:50:00",
    "code": "688606"
  },
  {
    "title": "明天有大“肉签”：一签有望赚10万 奥泰生物去年净利暴增近8倍",
    "href": "http://stock.jrj.com.cn/2021/03/14171632128302.shtml",
    "datetime": "2021-03-14 17:16:28",
    "code": "688606"
  },
  {
    "title": "奥泰生物(688606.SH)：发行价定为133.67元/股 3月15日申购",
    "href": "http://stock.jrj.com.cn/2021/03/11190532110564.shtml",
    "datetime": "2021-03-11 19:05:35",
    "code": "688606"
  },
  {
    "title": "证监会同意星球石墨、品茗股份、奥泰生物、西力科技科创板IPO注册",
    "href": "http://stock.jrj.com.cn/2021/02/18193031988024.shtml",
    "datetime": "2021-02-18 19:30:00",
    "code": "688606"
  },
  {
    "title": "奥泰生物冲击科创板：业绩增长靠“赊账” 收入靠出口",
    "href": "http://stock.jrj.com.cn/kcb/2020/11/23083731332325.shtml",
    "datetime": "2020-11-23 08:37:55",
    "code": "688606"
  },
  {
    "title": "奥泰生物寻求IPO 医疗器械集采后还有机会吗？",
    "href": "http://stock.jrj.com.cn/ipo/2020/11/04072231212753.shtml",
    "datetime": "2020-11-04 07:22:50",
    "code": "688606"
  },
  {
    "title": "奥泰生物：今年科创板过会第151家 申万宏源过4单",
    "href": "http://stock.jrj.com.cn/2020/10/22105631107080.shtml",
    "datetime": "2020-10-22 10:56:00",
    "code": "688606"
  },
  {
    "title": "西力科技、深科达、中望软件、奥泰生物10月21日科创板首发上会",
    "href": "http://stock.jrj.com.cn/2020/10/13085731041317.shtml",
    "datetime": "2020-10-13 08:57:00",
    "code": "688606"
  },
  {
    "title": "奥泰生物变道科创板IPO：自主品牌营收占比较低 募资逾50%用于产业化升级 | 产业新股",
    "href": "http://stock.jrj.com.cn/2020/09/29171430860468.shtml",
    "datetime": "2020-09-29 17:14:56",
    "code": "688606"
  },
  {
    "title": "每经小强快讯：前往科创板再下一城，百奥泰生物制药股份有限公司已获上交所问询",
    "href": "http://stock.jrj.com.cn/2019/08/05201127931914.shtml",
    "datetime": "2019-08-05 20:11:12",
    "code": "688606"
  },
  {
    "title": "卖壳分众传媒后 易贤忠携百奥泰生物制药再度冲击科创板",
    "href": "http://stock.jrj.com.cn/kcb/2019/07/29080227897271.shtml",
    "datetime": "2019-07-29 08:02:12",
    "code": "688606"
  },
  {
    "title": "每经小强快讯：百奥泰生物制药股份有限公司科创板首次公开发行股票招股说明书（申报稿）",
    "href": "http://stock.jrj.com.cn/2019/07/08190227810541.shtml",
    "datetime": "2019-07-08 19:02:01",
    "code": "688606"
  },
  {
    "title": "每经小强快讯：进军科创板，百奥泰生物制药股份有限公司申请已获上交所受理",
    "href": "http://stock.jrj.com.cn/2019/07/08190127810546.shtml",
    "datetime": "2019-07-08 19:01:57",
    "code": "688606"
  }
]